生长分化因子15与心血管风险:个体患者荟萃分析
结果显示GDF-15与心血管死亡和心衰住院在各动脉粥样硬化性心血管疾病(ASCVD)表现中均独立相关,但对心肌梗死和卒中的预后关联仅在近期ACS后稳定期或稳定ASCVD患者中显著,ACS急性期不显著。
要点
- GDF-15对心血管死亡和心衰住院的预后价值在ACS、近期ACS后稳定期及稳定ASCVD中一致。
- GDF-15对心肌梗死和卒中的预后关联仅在近期ACS后稳定期或稳定ASCVD中显著。
- ACS急性期GDF-15对心肌梗死和卒中无显著预后关联。
核心结论
- GDF-15在各ASCVD表现中一致提供心血管死亡和心衰住院的预后信息。
- GDF-15对心肌梗死和卒中的预后信息超出临床危险因素和心脏生物标志物,但ACS急性期不适用。
研究设计与样本
- 基线GDF-15作为连续变量及按既定切点(<1200 ng/L、1200-1800 ng/L、>1800 ng/L)分析。
- 采用Cox模型校正临床变量和已确立的心血管生物标志物。
- 按ASCVD状态分层:急性冠脉综合征(ACS)、近期ACS后稳定期、稳定ASCVD。
主要发现
- GDF-15浓度升高与心血管死亡/心衰住院和MACE发生率增加显著独立相关(每项P < 0.001)。
- GDF-15与心血管死亡和心衰住院在各ASCVD表现中均显示稳健且一致的独立关联。
- GDF-15与未来心肌梗死和卒中的预后关联仅在近期ACS后稳定期或稳定ASCVD患者中显著(心肌梗死HR 1.24,95%CI 1.17-1.31;卒中HR 1.16,95%CI 1.05-1.28)。
- ACS患者中GDF-15与心肌梗死和卒中无显著关联(心肌梗死HR 0.98,95%CI 0.90-1.06;卒中HR 0.87,95%CI 0.39-1.92)。
关键数值与推荐
- GDF-15切点:<1200 ng/L、1200-1800 ng/L、>1800 ng/L。
- 近期ACS后稳定期或稳定ASCVD患者中心肌梗死HR 1.24(95%CI 1.17-1.31),卒中HR 1.16(95%CI 1.05-1.28)。
- ACS患者中心肌梗死HR 0.98(95%CI 0.90-1.06),卒中HR 0.87(95%CI 0.39-1.92)。
临床怎么用
- GDF-15可用于ASCVD患者心血管死亡和心衰住院的风险分层。
- 在近期ACS后稳定期或稳定ASCVD患者中,GDF-15可辅助评估心肌梗死和卒中风险。
- ACS急性期GDF-15对心肌梗死和卒中的预后价值有限,需结合其他指标。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Levels of growth differentiation factor 15 (GDF-15), a cytokine secreted in response to cellular stress and inflammation, have been associated with multiple types of cardiovascular (CV) events. However, its comparative prognostic performance across different presentations of atherosclerotic cardiovascular disease (ASCVD) remains unknown. METHODS AND RESULTS: An individual patient meta-analysis was performed using data pooled from eight trials including 53 486 patients. Baseline GDF-15 concentration was analyzed as a continuous variable and using established cutpoints (<1200 ng/L, 1200-1800 ng/L, > 1800 ng/L) to evaluate its prognostic performance for CV death/hospitalization for heart failure (HHF), major adverse cardiovascular events (MACE), and their components using Cox models adjusted for clinical variables and established CV biomarkers. Analyses were further stratified on ASCVD status: acute coronary syndrome (ACS), stabilized after recent ACS, and stable ASCVD. Overall, higher GDF-15 concentration was significantly and independently associated with an increased rate of CV death/HHF and MACE (P < 0.001 for each). However, while GDF-15 showed a robust and consistent independent association with CV death and HHF across all presentations of ASCVD, its prognostic association with future myocardial infarction (MI) and stroke only remained significant in patients stabilized after recent ACS or with stable ASCVD [hazard ratio (HR): 1.24, 95% confidence interval (CI): 1.17-1.31 and HR: 1.16, 95% CI: 1.05-1.28 for MI and stroke, respectively] and not in ACS (HR: 0.98, 95% CI: 0.90-1.06 and HR: 0.87, 95% CI: 0.39-1.92, respectively). CONCLUSION: Growth differentiation factor 15 consistently adds prognostic information for CV death and HHF across the spectrum of ASCVD. GDF-15 also adds prognostic information for MI and stroke beyond clinical risk factors and cardiac biomarkers but not in the setting of ACS.
引用
- Kato, Morrow, Guo, et al. Growth differentiation factor 15 and cardiovascular risk: individual patient meta-analysis. Eur Heart J. 2023. PMID: 36303404. doi:10.1093/eurheartj/ehac577
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。